New technologies and care plans aim to enhance treatment options for patients in Mitchell and the surrounding area ...

A new class of non-opioid drugs treats pain by blocking signals before they reach the brain, reducing the risk of addiction.

The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class ...

A participant in the drug trial for Journavx said it eliminated her pain without making her feel loopy or nauseous ...